Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups
Orlowski, Robert Z., Moreau, Philippe, Niesvizky, Ruben, Ludwig, Heinz, Oriol, Albert, Chng, Wee Joo, Goldschmidt, Hartmut, Yang, Zhao, Kimball, Amy S., Dimopoulos, MeletiosLanguage:
english
Journal:
Clinical Lymphoma Myeloma and Leukemia
DOI:
10.1016/j.clml.2019.04.018
Date:
May, 2019
File:
PDF, 1.83 MB
english, 2019